Abstract Benzodiazepines represent the first-line treatment for the acute management of epileptic seizures and status epilepticus. The emergency use of benzodiazepines must be timely, and because most seizures occur outside of the hospital environment, there is a significant need for delivery methods that are easy for nonclinical caregivers to use and administer quickly and safely. In addition, the ideal route of administration should be reliable in terms of absorption. Rectal diazepam is the only licensed formulation in the USA, whereas rectal diazepam and buccal midazolam are currently licensed in the EU. However, the sometimes unpredictable absorption with rectal and buccal administration means they are not ideal routes. Several alternative routes are currently being explored. This is a narrative review of data about delivery methods for benzodiazepines alternative to the intravenous and oral routes for the acute treatment of seizures. Unconventional delivery options such as direct delivery to the central nervous system or inhalers are reported. Data show that intranasal diazepam or midazolam and the intramuscular auto-injector for midazolam are as effective as rectal or intravenous diazepam. Head-to-head comparisons with buccal midazolam are urgently needed. In addition, the majority of trials focused on children and adolescents, and further trials in adults are warranted.
Introduction
Benzodiazepines remain the first-line agents for the acute management of convulsive seizures and status epilepticus [1, 2] . However, their use in the long-term prophylactic treatment of epilepsy has been historically limited by two major problems: side effects, especially sedation, and the high potential for tolerance [3] . According to UK National Institute for Health and Care Excellence (NICE) guidelines, children, young people and adults with epilepsy should receive emergency care in case of prolonged (lasting more than 5 min) or repeated (three or more in an hour) convulsive seizures [4] . Diazepam, lorazepam and midazolam are the most widely used drugs in both adults and children. They have different pharmacokinetic profiles [5, 6] and are available in different pharmacological formulations [1, 7] ( Table 1) . For many years, rectal diazepam has been a very popular rescue medication and still represents the only outof-hospital treatment approved in the USA, but this route of administration is problematic and often socially unacceptable, especially in adults [8] . In the EU, buccal midazolam is also licensed for this indication and is now a widely used treatment in the community for patients with prolonged or repeated convulsive seizures. However, this route is also not ideal as absorption can still be unpredictable and any drug that is swallowed is then subject to metabolism and first-pass effects ( Table 2) .
The emergency use of benzodiazepines must be timely and, because most seizures occur outside of the hospital environment, there is a significant need for delivery methods that are easy for nonclinical caregivers to administer quickly and safely. Initiating an intravenous infusion system can be challenging and requires specially trained and competent personnel as well as various supplies. Several alternative routes are currently being explored. This is a narrative review of data about nonintravenous delivery methods for benzodiazepines in the acute treatment of seizures. References were identified via searches of MEDLINE until June 2016 using the terms epilepsy, benzodiazepines, acute repeated seizures, status epilepticus, and clinical trial. Additional publications were hand searched if relevant for the discussion.
Intranasal Delivery
The nasal cavity has three distinct functional areas: the vestibular, olfactory and respiratory zones. The rich vascularization of the olfactory and particularly the respiratory zone, with a total surface of approximately 145 cm 2 , means these areas may serve as efficient absorption surfaces for topical drugs [9] . Intranasal administration of benzodiazepines rapidly became attractive because the nasal cavity [5, 6, 10, 11, 37] is easily accessible and nasal absorption is not subject to the hepatic first-pass effect [10, 11] . In addition, absorption through the cribriform plate can lead to a rapid increase in drug concentrations in the cerebral spinal fluid (CSF) compared with other delivery methods, and this is obviously crucial for a brain disorder such as epilepsy [12] . However, intranasal administration is limited by a number of factors: (1) the extent of the nasal mucosa, (2) blood flow of the nasal mucosa and (3) potential mechanical drug loss anteriorly and posteriorly (Table 2) . For all these reasons, the delivering technology is a crucial factor in effective absorption. In fact, with liquid formulations or drops, the patient's head should be maintained in a specific position so the drug is not lost down the throat or outside the nasal cavity (i.e. the patient should be turned on his/her back with the head slightly hyperextended; if in a wheelchair, head back and hyperextended). Obviously this is not always possible during a convulsion, especially if prolonged. For this reason, spray or atomised pumps have been developed to obtain optimal mucosal distribution. Clinical studies on intranasal benzodiazepines for the acute management of seizures are available for midazolam [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] and lorazepam [23, 24] , suggesting that intranasal delivery is a potentially efficient alternative route of administration for both drugs (Table 3) , and ad hoc technologies are currently under investigation. In particular, two intranasal diazepam formulations are currently under development by Neurelis Inc. (10 mg) and Acorda Therapeutics (20 mg), and Upsher-Smith Laboratories are developing a midazolam intranasal formulation (2.5 mg, 5 mg, 7.5 mg) [10] . Development of intranasal midazolam is more advanced, as it is already under phase III; diazepam studies are still in phase I (Neurelis) and phase II (Acorda) [10] . Pharmacokinetic data show that absorption is more reliable and efficient than with the injectable solution, but data for patients with epilepsy in 'real-life' settings are still lacking.
A number of trials have compared intranasal midazolam with either rectal or intravenous diazepam [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] (Table 3) . Data suggest that intranasal midazolam is effective, safe and more efficient than rectal diazepam at controlling seizure activity [7] (Table 3) . Generally, midazolam has the advantage of faster absorption than diazepam, but its lower bioavailability and shorter half-life may be associated with an increased risk of recurrence [10] . Future studies comparing purpose-developed intranasal formulations of midazolam will be of interest. Data for intranasal lorazepam are limited to two studies (Table 3) showing efficacy similar to that of paraldehyde [24] and intravenous lorazepam [23] . However, paraldehyde is not a useful comparator as it is not generally considered a first-line agent; lorazepam is less lipophilic than midazolam, meaning it is not ideal for intranasal delivery.
Buccal Delivery
The buccal route is another transmucosal route and therefore has the same advantages, including rapid absorption and no first-pass effect ( Table 2 ). It is also easier to use than the intranasal and rectal routes. However, it is usually more suitable for drugs administered in small doses because if any is swallowed, that portion is treated as an oral dose and is subject to liver metabolism ( Table 2) . Midazolam is the most popular buccal formulation, and it has been investigated in a number of clinical trials [25] [26] [27] [28] [29] [30] [31] [32] [33] that have demonstrated its effectiveness over rectal diazepam in aborting seizure activity [34] . When comparing buccal midazolam and intravenous diazepam, the latter had a shorter mean time for controlling seizures, but buccal midazolam had a shorter mean time from initiation of treatment to seizure control [29] . Buccal midazolam is currently approved in the EU for the treatment of prolonged convulsive seizures in children and adolescents. It is available as Buccolam Ò (Shire Services) and Epistatus Ò (Special Products Limited). Buccolam Ò contains midazolam hydrochloride and comes in pre-filled oral syringes; Epistatus Ò contains midazolam maleate and comes in pre-filled syringes and a 5-ml bottle (10 mg/ml) with four syringes in the package. Suggested dosages range from 2.5 mg for patients aged between 6 and 12 months to 10 mg in patients aged over 10 years.
No studies have directly compared buccal and intranasal midazolam. An indirect comparison meta-analysis suggested no difference in efficacy or serious adverse events between the two transmucosal formulations of midazolam [35] . Despite the limitations of an indirect meta-analysis, similarities are easy to explain. In fact, it is the same compound, and the two routes of administration are both transmucosal, with the same pros and cons. Like intranasal midazolam, buccal midazolam has a short half-life, which carries the potential risk of seizure recurrence. Head-to-head comparisons and studies in adults are needed.
Sublingual Delivery
Another administration route within the oral mucosal cavity is the sublingual route, which differs slightly from the buccal route. The former is considered more permeable and capable of producing an even more rapid onset of action [36] ; this is based on the relative thickness and degree of keratinization of these tissues. In fact, although both are non-keratinized tissues, sublingual mucosa is thinner than buccal mucosa [36] . As such, it is important to highlight that drugs administered via the sublingual or buccal route involve different areas of the oral cavity: sublingual medications are given under the tongue, and buccal medications are placed towards the back of the mouth between the upper or lower molars and the cheek.
Although sublingual delivery affords very good bioavailability, absorption can be very slow [37] , and administration always requires the cooperation of the patient (Table 2) . Therefore, it appears evident that sublingual delivery is not ideal for patients experiencing a convulsive seizure. This is further supported by the only published randomised controlled trial in 436 children showing that sublingual lorazepam is less efficacious than rectal diazepam in controlling seizures [38] .
Intramuscular Auto-Injection
Although the intramuscular route cannot be considered innovative, the development of new devices for the autoinjection of benzodiazepines represents a novel delivery method permitting timely treatment of epileptic seizures. Both intramuscular lorazepam and diazepam are absorbed slowly, whereas intramuscular midazolam exhibits faster absorption (Table 1 ). In addition, the use of lorazepam in non-hospital settings is limited because the drug must be refrigerated. Thus, studies on the intramuscular route have focused on diazepam and midazolam.
Interestingly, the first auto-injector device for diazepam was developed by the US Army in the early 1990s for the immediate treatment of soman-induced seizures [39] . A phase I study investigating bioequivalence and dose proportionality showed that auto-injection of diazepam 10 mg in the anterolateral thigh was bioequivalent to diazepam injected with a conventional syringe [40] . This study also suggested that the site of injection is important because injection into the gluteus or deltoid muscles may lead to inconsistent absorption. Pfizer developed a specific device, and a double-blind randomised placebo-controlled phase III study showed that diazepam auto-injection was well tolerated and easy to use, with a significant reduction in time to next seizure compared with placebo, but it did not prevent hospitalisation or the need for further medical care [41] . The open-label extension study showed that 78% of injections resulted in no subsequent seizures or rescue during the post-dose follow-up period [42] . Head-to-head comparisons with buccal midazolam would be of great value.
A few studies have suggested that intramuscular midazolam is as effective as intravenous diazepam in the acute management of seizures in children [43, 44] , but safety and efficacy data for the auto-injector device for midazolam come mainly from the RAMPART study [45] [46] [47] . This double-blind randomized non-inferiority trial compared the efficacy of the intramuscular midazolam auto-injection with that of intravenous lorazepam for children and adults with epilepsy [46] . It demonstrated that pre-hospital treatment with intramuscular midazolam was at least as effective as intravenous lorazepam with the advantage that intramuscular treatments can be administered more quickly and reliably than intravenous treatments. A recent study showed similar figures in the paediatric population [47] , but more studies on the safety of the device and head-tohead comparisons are needed.
Unconventional Routes
Historically, drug delivery has been an important research topic for clinical pharmacologists. Non-oral administration routes, apart from those already discussed, would include the skin and airways (Table 4 ). It seems evident that transcutaneous administration is not particularly indicated in an emergency setting as absorption is usually slow and unreliable. The implant of a device releasing benzodiazepines subcutaneously may represent an interesting option, but no data about such a technique exist.
A few methods for delivering benzodiazepines via an inhalation route were developed many years ago (aerosol [48] and a dry powder for pulmonary absorption [49] ), but no further studies are available on these two methods. A singleblind study from China investigated the effect of an aerosol of diazepam and a mixture of Chinese herbs on epileptic auras and reported a 90% response rate [50] ; however, pharmacokinetic parameters and the concentration of diazepam administered were not provided. This study has not been replicated and did not lead to further controlled trials or the development of specific technologies.
Another potential administration route would be direct delivery to the central nervous system (CNS). A number of possible methods have been theorised (Table 4) , and some are already available for compounds other than benzodiazepines [51] . For example, intrathecal baclofen is very well known for the treatment of spasticity [52] , but this route may not be ideal for antiepileptic drugs as the brain distribution is usually very limited. Local perfusion via an implanted catheter attached to a pump programmed to infuse medications after detection of a seizure may represent an interesting option, and a proof-of-principal of this approach was presented in an animal model of epilepsy 20 years ago [53] . However, this method has a number of potential limitations, such as a high risk of respiratory depression and infections.
Drug wafers are another potential route for direct CNS delivery. They are made of a polymer matrix into which the drug is interwoven; it releases the medication over a prolonged period of time-from weeks to years. Although this approach may have a rationale for chemotherapy in brain tumours [54] , it is definitely not indicated for the delivery of benzodiazepines in the acute management of seizures.
Conclusions
Benzodiazepines are the first-line treatment for the acute management of epileptic seizures. Rectal diazepam and buccal midazolam are the only currently licensed formulations for benzodiazepine-apart from the usual oral and parenteral routes-but both have disadvantages, primarily related to unpredictable absorption. Data from the RAM-PART study clearly demonstrated the efficacy and safety of non-intravenous formulations of benzodiazepines in the acute management of seizures, and intramuscular midazolam was as effective as intravenous diazepam. A number of alternative methods are currently under investigation, and results are promising for intranasal delivery and an intramuscular auto-injection device. Pre-hospital rescue plans should be individualised on the basis of the patient's needs, age, and comorbidities potentially affecting absorption and distribution. Further studies are needed to establish the efficacy and safety of these methods and to develop new potential delivery methods for benzodiazepine in epilepsy.
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